Was betrifft es? Warum ist das wichtig?

A Clinical Study Report (CSR) is a summary describing the set-up, conduct, safety, and results of a study.

 

The CSR is also referred to:

  • In ICH GCP as a “Clinical trial / Study report” (CSR)
  • In ClinO-MD as a Clinical Investigation Report (CIR)
  • As a Final Study Report (FSR)

 

The aim of a CSR/CIR/FSR is to provide, among others, a summary regarding:

Mehr

he report has a “safety evaluation” section, where study safety data is evaluated and described on three levels:

  • Level 1: Extent of exposure: such as dose administered, duration of treatment, number of participants treated in the study (e.g. extent of exposure helps to decide the degree to which safety can be assessed from the study)
  • Level 2: Most common adverse events (Investigational Medicinal Product (IMP) = AE, Investigational Medical Device (IMD = ADE): including changes in laboratory test parameters
  • Level 3: Serious adverse events (IMP = SAE / SADR, IMD = SDE): a description of each death, serious adverse event, including the occurrence of other significant adverse events during study conduct

Was muss ich befolgen?

As a Site-INV, same procedures apply as defined for the annual safety report (e.g. the submission of safety data to the SP-INV)

 

As a SP-INV of a:

  • ClinO study, prepare CSR based on specifications provided in ICH E3 (structure and content of CSR)
  • ClinO-MD study, prepare a CIR based on Annex D in ISO 14155 (set-up and results of the clinical investigation)

 

Irrespective whether a study was completed or prematurely terminated, submit a CSR/CIR to:

 

Publication responsibilities:

  • Study results must be published irrespective whether they are positive, nonconclusive, or negative. This will help guide future research, device development and medical treatment.
  • To ensure research transparency, publish results in publicly accessible databases (e.g. study registries)
  • As applicable, enter results in a scientific publication
  • As applicable, provide study participants with study results

Mehr

A CSR/CIR is only written after:

  • The completion of the monitoring close-out visit
  • The Lock the study database and data export for data analysis
  • Completion of data analyses (e.g. according to SAP) and presentation of study results. In the event of a blinded study, unblinding only takes place after data analysis and the documentation of study results

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics – see in particular

  • Templates and checklists / Notifications
    • Study completion / discontinuation

Swissmedic – see in particular information sheet

  • BW101_10_003e_AA Instruction for reporting during the course of a study

References

ICH GCP E6(R3) – see in particular guideline

  • Glossary: definition of a CSR
  • 3.17.2 Clinical trial / Study reports
  • 6.2 Factors critical to quality
  • 7.3 Management of CtoQ factors

ICH E8(R1) – see in particular

  • 3.2 Critical to quality factors
  • 3.3 Approach to identify CtoQ factors
  • 5.6 Statistical analysis
  • 6.3 Study reporting

ICH E3 – Structure and Content of Clinical Study Reports

ISO 14155:2020 Medical device (access liable to cost) – see in particular annexes

  • 8.4 Clinical investigation report
  • Annex D Clinical investigational report
  • Annex F Adverse event categorization

Swiss Law

ClinO – see in particular article

  • Art. 38 Notification upon study completion, discontinuation or interruption
  • Art. 43 Reporting on the safety of participants
  • Art. 57b Reporting on the safety of participants
  • Art. 62d Applicable provisions

ClinO-MD – see in particular article

  • Art. 36 Notification of study termination or interruption
  • Art. 35 Annual reporting on the safety of participants
  • Art. 38 Notification and reporting to Swissmedic

HRO – see in particular articles

  • Art. 22, 36 and 40 Notification of study termination or interruption
Abkürzungen
  • AE - Adverse Event
  • ADE - Adverse Device Effect
  • BASEC – Business Administration System for Ethics Committees
  • CIR – Clinical Investigation Report
  • ClinO - Clinical Trials Ordinance
  • ClinO-MD - Ordinance on Clinical Trials with Medical Devices
  • CSR – Clinical Study Report
  • EC – Ethics Committee
  • eCRF – Electronic Data
  • FSR – Final Study Report
  • HRO – Human Research Ordinance
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation - Good Clinical Practice
  • IMD – Investigational Medical Device
  • IMP – Investigational Medicinal Product
  • ISO - International Organization for Standardization
  • SADR - Serious Adverse Drug Reaction
  • SAE – Serious Adverse Event
  • SAP – Statistical Analysis Plan
  • SDE – Serious Device Effect
  • Site-INV – Site Investigator
  • SP-INV – Sponsor Investigator
Completion ↦ Safety ↦ Clinical Study Report ↦ Procedures
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Completion ↦ Safety ↦ Clinical Study Report ↦ Procedures